fr Contact us

Vascepa®: Power to reduce the risk of cardiovascular events1

Vascepa® demonstrated reductions in the risk of CV events vs. placebo (both in combination with statins)1*

2° endpoints

Vascepa® demonstrated a significant 25% reduction (event n=705 vs. 901) in time to first occurrence of cardiovascular death, MI, stroke, coronary revascularization or hospitalization for unstable angina (5-point MACE) vs. placebo (1° endpoint)1*
95% CI (0.68, 0.83)

There was no statistically significant difference in risk between the Vascepa® and placebo groups for all-cause mortality.

Contact us

A placebo-controlled trial with a 4.9-year median follow-up of statin-treated adult patients with elevated triglycerides and a high risk of cardiovascular events due to established cardiovascular disease or diabetes with at least 1 other CV risk factor.1*

Consider Vascepa®: The first and ONLY icosapent ethyl (IPE) prescription medication

Vascepa® (icosapent ethyl) is indicated to reduce the risk of cardiovascular events (cardiovascular death, non-fatal myocardial infarction, non-fatal stroke, coronary revascularization or hospitalization for unstable angina) in statin-treated patients with elevated triglycerides, who are at high risk of cardiovascular events due to:

* 8,179 statin-treated adult patients with elevated serum triglyceride levels (≥1.5 mmol/L to <5.6 mmol/L) who were also at high risk for atherothrombotic events. Patients either had established CVD or were at high risk for CVD and were randomized to either Vascepa® or placebo. Patients with established cardiovascular disease were at least 45 years of age and had a documented history of coronary artery disease, cerebrovascular or carotid disease, or peripheral artery disease. Patients with other risk factors for cardiovascular disease were at least 50 years of age and had diabetes and at least one additional major cardiovascular risk factor. 5-point MACE was defined as time to first occurrence of cardiovascular death, myocardial infarction, stroke, hospitalization for unstable angina, or coronary revascularization. Most patients at baseline were taking at least one other cardiovascular medication including anti-hypertensives (95%), anti-platelet agents (79.4%), beta blockers (70.7%), angiotensin-converting enzyme (ACE) inhibitors (51.9%), and angiotensin receptor blockers (ARB) (27.0%), with 77.5% taking either an ACE inhibitor or ARB. At baseline, while on stable background lipid-lowering therapy, the median LDL-C was 1.9 mmol/L.
Incidence rates of CV events per 100 patient years (Vascepa® vs. placebo): cardiovascular death, 1.0 vs. 1.2; non-fatal myocardial infarction, 1.4 vs. 2.0; non-fatal stroke, 0.5 vs. 0.7.
CV death includes adjudicated cardiovascular deaths and deaths of undetermined causality.
§ Comparative clinical significance has not been established.
CI, confidence interval; CV, cardiovascular; CVD, cardiovascular disease; LDL-C, low-density lipoprotein cholesterol; MACE, major adverse cardiovascular event.

Reference:
1. HLS Therapeutics Inc. Vascepa® Product Monograph. 2019.

Safety Information

Vascepa® is a registered trademark of the Amarin group of companies.

© 2020 HLS Therapeutics Inc.
HLS Therapeutics Inc.
Etobicoke, Ontario
M9W 6L2